CEO SUMMARY: In Ireland, the big story in healthcare at the moment is the discovery that the nation’s cervical cancer screening program has failed hundreds of women who had pre-cancerous conditions or cervical cancer, but, as alleged in numerous court cases, their tests were inaccurate or the results not communicated to their physicians, or both.
Tag: smear test
CEO SUMMARY: Last month, in Seattle, Washington, a jury ordered Laboratory Corporation of America and Valley Medical Center each to pay $25 million following a lawsuit about a ‘wrongful’ birth. At issue was how genetic tests were ordered, performed, and reported. This court case is the latest example of the heightened legal risk labs face
Much is happening in the anatomic pathology market in the Pacific Northwest. PAML, LLC (Spokane, Washington), and CellNetix (Seattle, Washington) finally executed the agreement whereby PAML made an equity investment in CellNetix. Now, the two lab companies will collaborate on developing a reference and esoteric anatomic pathology testing service with national ambitions. Within days of
CEO SUMMARY: Pathologists worldwide are witnessing how a government health service can erode its nation’s pathology capabilities in cytology. Ireland’s experiment in off-shoring all its Pap testing even as it requires women to register in a national database in order to get free cervical cancer screening is not turning out well. A growing number of
WHEN IT COMES TO CERVICAL CANCER SCREENING IN IRELAND, health system bureaucrats have put some of the nation’s women into the perfect “Catch 22.”
As this happens, it provides another case study of why a government health system can often create coverage rules and restrictions which run contrary to common sense in patient care, while at
USE OF LEAN METHODS HAS UNLOCKED major improvements at Baystate Health’s Department of Pathology in Springfield, Massachusetts. One Lean project cut average Pap test turnaround time by more than 50%. Another Lean project attacked errors with Advanced Beneficiary Notices (ABN), leading to a 75% reduction in write-offs, worth $1 million!
In the first case, the lab
CEO SUMMARY: Guided Therapeutics, Inc. of Norcross, Georgia is working to develop proprietary technology into an improved method for detecting cervical cancer. It wants to give ob-gyns and other physicians an instrument system that can be used in the office to provide real-time results to patients. The procedure will be non-invasive and it will determine
CEO SUMMARY: At least ten companies are working on an HPV vaccine that can prevent cervical cancer. The leading two companies have Phase III clinical trials under way and expect to earn regulatory approval within the next 24 to 30 months. The speedy arrival of an HPV vaccine in the market will not affect Pap
CEO SUMMARY: Because cervical cancer screening involves more than 55 million Pap tests per year in the United States, it is a high-profile segment of the lab testing industry. HPV testing is making steady inroads into the cervical cancer screening process. Digene Corporation is the direct beneficiary of this, but Cytyc Corporation and TriPath Imaging
CEO SUMMARY: As new diagnostic technologies move through the development pipeline and into widespread clinical use, the scientific knowledge and skill sets needed by laboratory staff and management will change. The emphasis in laboratory medicine will evolve to include more molecular technology, but this evolution will proceed incrementally, giving all laboratories time to adapt.